Marie-Claire Chapuy

TL;DR: Findings indicate an impairment of osteoblastic function, with depression of bone formation at all levels, and strongly suggest a toxic effect of Al on osteoblasts.

TL;DR: There is a clear correlation between the efficacy and the occurrence of side effects of fluoride therapy in osteoporosis and the bioavailability of the fluoride salt may play a critical role in the magnitude of the response and should be taken into account when establishing the optimum therapeutic dose, as the therapeutic window may be narrow.

TL;DR: Sixteen patients with Paget's disease of bone and well-documented resistance to sodium etidronate were treated with a new diphosphonate, aminohexane diph phosphate, given orally for three months at a daily dose of 400 mg, accompanied by marked clinical improvement, a reduction of the radioisotope uptake by pagetic bones, and radiologic healing of osteolytic lesions in some cases.

TL;DR: A diphosphonate free of such a side-effect would be preferable for the treatment of not only Paget’s disease, but of any other condition of hyperosteoclastosis, whatever the mechanisms of osteoclastic differenciation.

TL;DR: It appears that a rapid bone load with oral Cl2MDP can induce a long-lasting reduction in bone resorption excess, as well as the greatest reduction in serum alkaline phosphatase.